Institute For Basic Research in New York seeking adults with Fragile X for New Clinical Trial

Source: 
October 17, 2011
Abstract: 

The Institute for Basic Research in Staten Island is seeking adult participants for a new Fragile X treatment trial. This is a large scale trial of AFQ056 from Novartis for people aged 18-45 who have Fragile X. AFQ056 is an mGluR5 antagonist. The current study is just for adults but the next step is to extend the trial to ages 12-17. After completing the 20 week trial, participants will be offered the option of taking this medication free of charge until it comes to market.

The Institute for Basic Research in Staten Island is seeking adult participants for a new Fragile X treatment trial. 

This is a large scale trial of AFQ056 from Novartis for people aged 18-45 who have Fragile X.  AFQ056 is an mGluR5 antagonist.  The current study is just for adults but the next step is to extend the trial to ages 12-17.  After completing the 20 week trial, participants will be offered the option of taking this medication free of charge until it comes to market.

The principal investigator on this study is Dr. Angelo Porto, Dept. of Psychology, Institute for Basic Research(IBR). porto_a@medscape.com or 718-494-8028

Additional information about AFQ056 and the study can be found at fraxa.org/getInvolved_studies.aspx